CSMC, IIT2016-09-LABADZHYAN-ICI, met ca, predictive markers/endocrine hormone changes

Summary

Aim 1: To show that specific endocrine related antibodies, known to be associated with endocrine gland failure, are a good predictive marker for development of endocrine related adverse events (ERAE) in patients with metastatic cancers treated with immune checkpoint regulators. To accomplish this aim, we will measure anti thyroid peroxidase antibody (Anti-TPO), anti thyroglobulin (anti-TG), thyroid stimulating immunoglobulin (TSI), anti glutamic acid decarboxylase (anti-GAD), and anti-adrenal antibodies before initiation of treatment and at the time of endocrine adverse event development. Aim 2: To determine how changes in levels of pituitary, thyroid, adrenal, and diabetes hormones predict development of ERAE. To accomplish this goal we will measure pituitary hormones, thyroid function tests, cortisol levels, and fasting blood sugar prior to treatment and at specified treatment intervals. Aim 3: To examine whether the specific type of immune checkpoint regulator used for treatment is associated with development of an ERAE.


Inclusion Criteria

Not Available


Study Location(s)

  • Cedars-Sinai Cancer at SOCC
  • Cedars-Sinai Cancer at The Angeles Clinic and Research Institute



Full Title

IIT2016-09-LABADZHYAN-ICI: Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors.

Details
Disease Type/Condition

Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kaposi's sarcoma, Kidney, Larynx, Leukemia, not otherwise specified, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Urinary Bladder

Principal Investigator

Labadzhyan, Artak

Co-Investigators

Mourad Tighiouart, Omid Hamid, Robert Figlin, Shlomo Melmed, Stephen Shiao

Age Group

Adult

Phase

N/A

IRB Number

Pro00045026


Contact
Email
cancer.trial.info@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Anus, Bones and Joints, Brain and Nervous System, Breast, Cervix, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Ill-Defined Sites, Kaposi's sarcoma, Kidney, Larynx, Leukemia, not otherwise specified, Leukemia, other, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, Multiple Myeloma, Mycosis Fungoides, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Hematopoietic, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Unknown Sites, Urinary Bladder

Principal Investigator

Labadzhyan, Artak

Age Group

Adult

Phase

N/A

IRB Number

IIT2016-09-LABADZHYAN-ICI


Contact
Email
cancer.trial.info@cshs.org
Want to join the study or
learn more?